Australian National Enterovirus Reference Laboratory annual report, 2020
DOI:
https://doi.org/10.33321/cdi.2021.45.56Keywords:
poliovirus, acute flaccid paralysis, surveillance, enterovirus, poliomyelitis, eradication, vaccinationAbstract
Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2020, no cases of poliomyelitis were reported from clinical surveillance; Australia reported 1.09 non-polio AFP cases per 100,000 children, thereby meeting the WHO’s performance criterion for a sensitive surveillance system. The non-polio enteroviruses coxsackievirus A10 and coxsackievirus A16 were identified from clinical specimens collected from AFP cases. Australia also performs enterovirus surveillance and environmental surveillance to complement the clinical system focussed on children. In 2020, there were 140 cases of wild poliovirus reported from the two remaining endemic countries: Afghanistan and Pakistan. Another 28 countries reported cases of circulating vaccine-derived poliovirus.
Downloads
References
Aylward RB. Poliomyelitis. In Heymann, DL, ed. Control of Communicable Diseases Manual. 20th ed. Fort Worth: APHA Press, 2015;477–84. doi: https://doi.org/10.2105/CCDM.2745.116.
Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213–29.
World Health Organization (WHO). Poliomyelitis. [Internet.] Geneva: WHO; 22 July 2019. [Accessed on 29 March 2021.] Available from: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis.
Adams T. Farewell to polio in the Western Pacific. Bull World Health Organ. 2000;78(12):1375.
Australian Paediatric Surveillance Unit (APSU). Study Protocol, Acute Flaccid Paralysis. [Internet.] APSU, 2014. [Accessed on 29 March 2021.] Available from: http://www.apsu.org.au/assets/current-studies/AFP-Study-Protocol-June-2014.pdf.
Paediatric Active Enhanced Disease Surveillance (PAEDS). Surveillance and research: acute flaccid paralysis. [Internet.] Sydney: National Centre for Immunisation Research and Surveillance, PAEDS; 2021. [Accessed on 29 March 2021.] Available from: http://www.paeds.org.au/our-work/surveillance-and-research.
Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26(1):75. doi: https://doi.org/10.1186/s12929-019-0573-2.
Sun J, Hu XY, Yu XF. Current understanding of human enterovirus D68. Viruses. 2019;11(6):490. doi: https://doi.org/10.3390/v11060490.
WHO. Global wild poliovirus 2016-2021. Geneva: WHO; 23 March 2021. [Accessed on 29 March 2021.] Available from: https://polioeradication.org/wp-content/uploads/2021/03/weekly-polio-analyses-WPV-20210323.pdf.
Zomahoun DJ, Burman AL, Snider CJ, Chauvin C, Gardner T, Lickness JS et al. Impact of COVID-19 pandemic on global poliovirus surveillance. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1648–52.
WHO. Global polio eradication initiative: ending polio. Geneva: WHO. [Accessed on 31 March 2021.] Available from: https://polioeradication.org/wp-content/uploads/2020/04/GPEI-fact-sheet-20191113.pdf.
Africa Regional Commission for the Certification of Poliomyelitis Eradication. Certifying the interruption of wild poliovirus transmission in the WHO Africa region on the turbulent journey to a polio-free world. Lancet Glob Health. 2020;8(10):e1345–51. doi: https://doi.org/ 10.1016/S2214-109X(20)30382-X.
WHO, Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. [Internet.] Geneva: WHO; 23 March 2021. [Accessed on 29 March 2021.] Available from: https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.
Australian Government Department of Health. Poliovirus infection. [Internet.] Canberra: Australian Government Department of Health; 1 January 2015. [Accessed on 29 March 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_polio.htm.
WHO. Vaccine-preventable diseases: surveillance standards. Poliomyelitis. Last updated September 5, 2018. Geneva: WHO; 5 September 2018. [Accessed on 29 March 2021.] Available from: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_18_Polio_R2.pdf.
Wood DJ, Hull B. L20B cells simplify culture of polioviruses from clinical samples. J Med Virol. 1999;58(2);188–92.
WHO. Polio Laboratory Manual, 4th edition. (WHO/IVB/04.10) Geneva: WHO, Department of Immunization, Vaccines and Biologicals; 2004.
Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J, Campagnoli R et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol. 2009;47(6):1939–41.
Stewardson AJ, Roberts JA, Beckett CL, Prime HT, Loh PS, Thorley BR et al. Imported case of poliomyelitis in Melbourne, Australia. Emerg Infect Dis. 2009;15(1):63–5.
WHO. Guidelines for environmental surveillance of poliovirus circulation. (WHO/V&B/03.03) Geneva: WHO, Department of Vaccines and Biologicals; 2003.
Roberts JA. Thesis. “Chapter 2: Development of a Novel Enterovirus Detection and Super-Speciation Assay”, An integrated bioinformatics and computational biophysics approach to enterovirus surveillance and research. RMIT University, 2014: 62-109. [Accessed on 31 March 2021.] Available from: https://researchbank.rmit.edu.au/view/rmit:162129.
May M, Durrheim D, Roberts JA, Owen R. The risks of medical complacency towards poliomyelitis. Med J Aust. 2020;213(2):61–3. doi: https://doi.org/10.5694/mja2.50681.
Australian Government Department of Health. A poliovirus reintroduction and outbreak risk assessment methodology for Australia. Version 1. Canberra: Australian Government Department of Health; January 2019. [Accessed on 31 March 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/00E5FF11E270AB07CA257CD200024CCE/$File/Polio-RA-methodology.pdf.
Bruggink LD, Garcia-Clapes A, Tran T, Druce JD, Thorley BR. Decreased incidence of enterovirus and norovirus infections during the COVID-19 pandemic, Victoria, Australia, 2020. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.5.
Sullivan SG, Carlson S, Cheng AC, Chilver MBN, Dwyer DE, Irwin M et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Euro Surveill. 2020;25(47):2001847. doi: https://doi.org/10.2807/1560-7917.ES.2020.25.47.2001847.
Macklin GR, O’Reilly KM, Grassly NC, Edmunds WJ, Mach O, Santhana Gopala Krishnan R et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368(6489):401–5.
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50. doi: https://doi.org/10.1016/S0140-6736(20)32541-1.
WHO. WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of OPV use: GAPIII. Geneva: WHO; 2015. [Accessed on 31 March 2021.] Available from: https://apps.who.int/iris/handle/10665/208872.
Published
How to Cite
License
Copyright (c) 2021 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
